研究发现,CGRP抑制剂乌布罗杰潘特可减少偏头痛的残疾,并在早期治疗后改善功能. Study finds ubrogepant, a CGRP inhibitor, reduces migraine disability and improves function after early treatment.
一项发表在"神经学"杂志上的研究表明,一款CGRP抑制剂乌布罗杰潘特 (ubrogepant) 可能有助于预防偏头痛, A study published in Neurology suggests that ubrogepant, a CGRP inhibitor, may help prevent migraines when taken at the first signs of an attack. 在这项研究中,518名有偏头痛和预警迹象的参与者在两个月内处理了两次袭击。 In the study, 518 participants with migraine and early warning signs treated two attacks during a two-month period. 研究人员发现,与安慰剂患者相比,服用乌布罗杰潘特的参与者报告残疾较少,治疗后24小时正常运作的可能性更高. Researchers found that participants who took ubrogepant reported less disability and were more likely to function normally 24 hours after treatment compared to placebo recipients. 早期使用乌布罗杰潘特治疗可能使患者能够在最早的阶段迅速治疗偏头痛并改善日常生活. Early treatment with ubrogepant may allow individuals to quickly treat migraines in their earliest stages and improve daily life.